The impact of human and mouse differences in NOS2 gene expression on the brain’s redox and immune environment

BackgroundMouse models are used in the study of human disease. Despite well-known homologies, the difference in immune response between mice and humans impacts the application of data derived from mice to human disease outcomes. Nitric oxide synthase-2 (NOS2) is a key gene that displays species-specific outcomes via altered regulation of the gene promoter and via post-transcriptional mechanisms in humans that are not found in mice. The resulting levels of NO produced by activation of human NOS2 are different from the levels of NO produced by mouse Nos2. Since both tissue redox environment and immune responsiveness are regulated by the level of NO and its interactions, we investigated the significance of mouse and human differences on brain oxidative stress and on immune activation in HuNOS2tg/mNos2-/- mice that express the entire human NOS2 gene and that lack a functional mNos2 compared to wild type (WT) mice that express normal mNos2.Methods/resultsSimilarly to human, brain tissue from HuNOS2tg/mNos2-/- mice showed the presence of a NOS2 gene 3′UTR binding site. We also identified miRNA-939, the binding partner for this site, in mouse brain lysates and further demonstrated reduced levels of nitric oxide (NO) typical of the human immune response on injection with lipopolysaccharide (LPS). HuNOS2tg/mNos2-/- brain samples were probed for characteristic differences in redox and immune gene profiles compared to WT mice using gene arrays. Selected genes were also compared against mNos2-/- brain lysates. Reconstitution of the human NOS2 gene significantly altered genes that encode multiple anti-oxidant proteins, oxidases, DNA repair, mitochondrial proteins and redox regulated immune proteins. Expression levels of typical pro-inflammatory, anti-inflammatory and chemokine genes were not significantly different with the exception of increased TNFα and Ccr1 mRNA expression in the HuNOS2tg/mNos2-/- mice compared to WT or mNos2-/- mice.ConclusionsNO is a principle factor in establishing the tissue redox environment and changes in NO levels impact oxidative stress and immunity, both of which are primary characteristics of neurodegenerative diseases. The HuNOS2tg/mNos2-/- mice provide a potentially useful mechanism to address critical species- specific immune differences that can impact the study of human diseases.

[1]  R. Guerreiro,et al.  Complement receptor 1 (CR1) and Alzheimer's disease. , 2012, Immunobiology.

[2]  P. Haley.  Species differences in the structure and function of the immune system. , 2003, Toxicology.

[3]  N. Schor.  What the halted phase III γ‐secretase inhibitor trial may (or may not) be telling us , 2011, Annals of Neurology.

[4]  P. Mcgeer,et al.  Brain microglia constitutively express beta-2 integrins. , 1990, Journal of neuroimmunology.

[5]  L. Tran,et al.  Integrated Systems Approach Identifies Genetic Nodes and Networks in Late-Onset Alzheimer’s Disease , 2013, Cell.

[6]  O. Augusto,et al.  Connecting the chemical and biological properties of nitric oxide. , 2012, Chemical research in toxicology.

[7]  P. Tripathi.  Nitric oxide and immune response. , 2007, Indian journal of biochemistry & biophysics.

[8]  G. Perry,et al.  Metabolic, metallic, and mitotic sources of oxidative stress in Alzheimer disease. , 2000, Antioxidants & redox signaling.

[9]  O. Devuyst,et al.  A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. , 2000, Kidney international.

[10]  Jeffrey F. Thompson,et al.  Matrix Metalloproteinase-Mediated Disruption of Tight Junction Proteins in Cerebral Vessels is Reversed by Synthetic Matrix Metalloproteinase Inhibitor in Focal Ischemia in Rat , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[11]  A. Paganini-Hill,et al.  Comparative Analysis of H&E and Prussian Blue Staining in a Mouse Model of Cerebral Microbleeds , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[12]  W. Griffin,et al.  Glial‐Neuronal Interactions in Alzheimer's Disease: The Potential Role of a ‘Cytokine Cycle’ in Disease Progression , 1998, Brain pathology.

[13]  Bino John,et al.  miRNA-939 regulates human inducible nitric oxide synthase posttranscriptional gene expression in human hepatocytes , 2012, Proceedings of the National Academy of Sciences.

[14]  C. Colton,et al.  Species differences in the generation of reactive oxygen species by microglia , 1996, Molecular and chemical neuropathology.

[15]  T. L. Taylor,et al.  Activation of matrix metalloproteinases following anti-Aβ immunotherapy; implications for microhemorrhage occurrence , 2011, Journal of Neuroinflammation.

[16]  C. Colton,et al.  Mechanisms of the antioxidant effects of nitric oxide. , 2001, Antioxidants & redox signaling.

[17]  Christoph Lange,et al.  Genome-wide association analysis reveals putative Alzheimer's disease susceptibility loci in addition to APOE. , 2008, American journal of human genetics.

[18]  N. Maeda,et al.  Type III hyperlipoproteinemia and spontaneous atherosclerosis in mice resulting from gene replacement of mouse Apoe with human Apoe*2. , 1998, The Journal of clinical investigation.

[19]  R. Floyd.  Antioxidants, oxidative stress, and degenerative neurological disorders. , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[20]  S. Hussain,et al.  Regulation of human nitric oxide synthase 2 expression by Wnt beta-catenin signaling. , 2006, Cancer research.

[21]  T. Miyakawa,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013 .

[22]  David A. Geller,et al.  Multiple NF-κB Enhancer Elements Regulate Cytokine Induction of the Human Inducible Nitric Oxide Synthase Gene* , 1998, The Journal of Biological Chemistry.

[23]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[24]  Seth Love,et al.  Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease , 2010, PloS one.

[25]  P. Mcgeer,et al.  Reactive microglia in patients with senile dementia of the Alzheimer type are positive for the histocompatibility glycoprotein HLA-DR , 1987, Neuroscience Letters.

[26]  S. Ambs,et al.  Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer , 2011, Cell cycle.

[27]  J. Fukuto,et al.  A comparison of the chemistry associated with the biological signaling and actions of nitroxyl (HNO) and nitric oxide (NO). , 2013, Journal of inorganic biochemistry.

[28]  Alin Ciobica,et al.  The oxidative stress hypothesis in Alzheimer's disease. , 2013, Psychiatria Danubina.

[29]  C. Finch,et al.  Evolutionary perspectives on amyloid and inflammatory features of Alzheimer disease , 1996, Neurobiology of Aging.

[30]  M. Nieto,et al.  Nitric oxide in the cerebral cortex of amyloid-precursor protein (SW) Tg2576 transgenic mice , 2004, Neuroscience.

[31]  M. Sabbagh,et al.  Clinical trial of an inhibitor of RAGE-Aβ interactions in Alzheimer disease , 2014, Neurology.

[32]  C. Colton,et al.  Nitric oxide‐mediated regulation of β ‐amyloid clearance via alterations of MMP‐9/TIMP‐1 , 2012, Journal of neurochemistry.

[33]  R. Gamelli,et al.  Genomic responses in mouse models poorly mimic human inflammatory diseases , 2013, Proceedings of the National Academy of Sciences.

[34]  D. Geller,et al.  Complex regulation of human inducible nitric oxide synthase gene transcription by Stat 1 and NF-κB , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[35]  C. Harris,et al.  The chemical biology of nitric oxide: implications in cellular signaling. , 2008, Free radical biology & medicine.

[36]  Kyung Soo Park,et al.  Identification of a classic cytokine‐induced enhancer upstream in the human iNOS promoter , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  D. Geller,et al.  Cytokine induction of NO synthase II in human DLD‐1 cells: roles of the JAK‐STAT, AP‐1 and NF‐κB‐signaling pathways , 1998, British journal of pharmacology.

[38]  D. Wink,et al.  The chemistry of nitrosative stress induced by nitric oxide and reactive nitrogen oxide species. Putting perspective on stressful biological situations , 2004, Biological chemistry.

[39]  J. Weinberg,et al.  Human mononuclear phagocyte inducible nitric oxide synthase (iNOS): analysis of iNOS mRNA, iNOS protein, biopterin, and nitric oxide production by blood monocytes and peritoneal macrophages. , 1995, Blood.

[40]  R. Mrak,et al.  Glia and their cytokines in progression of neurodegeneration , 2005, Neurobiology of Aging.

[41]  C. Colton,et al.  Nitric oxide and redox mechanisms in the immune response , 2011, Journal of leukocyte biology.

[42]  R. Veerhuis,et al.  Neuroinflammation – An Early Event in Both the History and Pathogenesis of Alzheimer’s Disease , 2010, Neurodegenerative Diseases.

[43]  D. Wink,et al.  Asbestos redirects nitric oxide signaling through rapid catalytic conversion to nitrite. , 2006, Cancer research.

[44]  C. Colton,et al.  Sex steroids, APOE genotype and the innate immune system , 2005, Neurobiology of Aging.

[45]  L. Kobzik.  Translating NO biology into clinical advances: still searching for the right dictionary? , 2009, American journal of respiratory cell and molecular biology.

[46]  D. Wilcock,et al.  Passive immunotherapy against Aβ in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage , 2004, Journal of Neuroinflammation.

[47]  S. Younkin,et al.  Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice , 1996, Science.

[48]  Nastaran Gharkholonarehe,et al.  Progression of Amyloid Pathology to Alzheimer's Disease Pathology in an Amyloid Precursor Protein Transgenic Mouse Model by Removal of Nitric Oxide Synthase 2 , 2008, The Journal of Neuroscience.

[49]  J. Rodrigo,et al.  Expression of nitric oxide system in clinically evaluated cases of Alzheimer's disease , 2004, Neurobiology of Disease.

[50]  R. Braman,et al.  Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. , 1989, Analytical chemistry.

[51]  Michael P Vitek,et al.  Characterization of NO and cytokine production in immune-activated microglia and peritoneal macrophages derived from a mouse model expressing the human NOS2 gene on a mouse NOS2 knockout background. , 2006, Antioxidants & redox signaling.

[52]  James B. Mitchell,et al.  Superoxide Fluxes Limit Nitric Oxide-induced Signaling* , 2006, Journal of Biological Chemistry.

[53]  S. Ambs,et al.  Molecular mechanisms for discrete nitric oxide levels in cancer. , 2008, Nitric oxide : biology and chemistry.

[54]  M. Schneemann,et al.  Macrophage biology and immunology: man is not a mouse , 2007, Journal of leukocyte biology.

[55]  P. Mcgeer,et al.  Brain microglia constitutively express β-2 integrins , 1990, Journal of Neuroimmunology.

[56]  C. Colton,et al.  The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. , 2008, Journal of Alzheimer's disease : JAD.

[57]  Brigitte Wildemann,et al.  Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with β-amyloid 1–42 in vitro , 2002, Neuroscience Letters.

[58]  M. Goedert,et al.  The value of incomplete mouse models of Alzheimer’s disease , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[59]  J. Hardy,et al.  TREM2 and neurodegenerative disease. , 2013, The New England journal of medicine.

[60]  M A Pericak-Vance,et al.  Genome-wide association study of Alzheimer's disease , 2012, Translational Psychiatry.

[61]  H. Lassmann,et al.  Explorer NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury , 2012 .

[62]  Keizo Takao,et al.  Genomic responses in mouse models greatly mimic human inflammatory diseases , 2014, Proceedings of the National Academy of Sciences.

[63]  R. Koehler,et al.  Dopamine Receptor Modulation of Hypoxic—Ischemic Neuronal Injury in Striatum of Newborn Piglets , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[64]  T. Billiar,et al.  Molecular biology of nitric oxide synthases , 1998, Cancer and Metastasis Reviews.

[65]  T. Malinski.  Nitric oxide and nitroxidative stress in Alzheimer's disease. , 2007, Journal of Alzheimer's disease : JAD.

[66]  C. Colton.  Induction of nitric oxide in cultured microglia: evidence for a cytoprotective role. , 1995, Advances in neuroimmunology.

[67]  C. Harris,et al.  p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells , 1998, Nature Medicine.

[68]  Teemu Laitinen,et al.  mNos2 Deletion and Human NOS2 Replacement in Alzheimer Disease Models , 2014, Journal of neuropathology and experimental neurology.

[69]  Nick C Fox,et al.  Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. , 2014, The New England journal of medicine.

[70]  R. Banerjee,et al.  Nitrite Reductase Activity and Inhibition of H2S Biogenesis by Human Cystathionine ß-Synthase , 2014, PloS one.

[71]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[72]  N. Greig,et al.  Why do so many drugs for Alzheimer's disease fail in development? Time for new methods and new practices? , 2008, Journal of Alzheimer's disease : JAD.

[73]  K. Morgan,et al.  The three new pathways leading to Alzheimer's disease , 2011, Neuropathology and applied neurobiology.